Mistletoe Therapy

White-berried European Mistletoe extracts (Viscum album) is a medicinal plant that has been used since ancient times. Mistletoe extracts are the most frequently prescribed unconventional cancer treatment in Central Europe. Mistletoe therapy and its use in cancer treatment began in the early 1900s.

There are over 150 scientific publications examining the efficacy of mistletoe therapy as either a monotherapy or an adjunct therapy for patients with cancer.

How it works?

Our immune system can identify and destroy malignant cells, therefore a dysfunctional immune system can leave a person more susceptible to cancer.  Mistletoe stimulates the body’s immune system which inhibits cancer cell growth by surrounding the tumour with immune cells, thus preventing the spread of the cancer without harming healthy tissues. Mistletoe activates the body’s immune system, allowing the body to play an active role in the healing process.


Mistletoe therapy is administered by subcutaneous injection into constantly changing sites of the abdomen, thigh or upper arm.

The frequency of injections is three time a week.  In rapidly progressive cases, daily injections may be necessary.

The treatment always begins with low doses.  The dose is increased gradually, according to the patient’s reaction, until the therapeutic dose is reached.  If the disease is advanced, a higher dosage is usually required.

Possible Side Effects

Mistletoe that is administered properly is generally well tolerated.  Berries taken orally are highly toxic and considered highly poisonous.  When injected subcutaneously, on rare occasions there is an allergic reaction usually appearing as generalized itching or skin rash.  Other possible side effects include swelling of lymph nodes, general malaise with shivering, headache, limb pain, dizziness, chills, high fever, angina, and orthostatic circulatory disturbances.

Often there is redness and swelling that develops at the injection site.  Also, there is often a slight rise in temperature.  These are actually positive reactions, indicating that the immune system is being activated.   A local reaction in response to the mistletoe injection has been associated with better T-lymphocyte function, which demonstrates an activation of the immune system.

Treatment should be interrupted until symptoms disappear and doses should be adjusted if localized swelling is larger than 5cm in diameter or temperature is over 38ºC.

It is important that patients receiving mistletoe therapy are administered and being closely monitored by a health care practitioner who is well-trained and knowledgeable about this unconventional treatment, as there are serious risks if this therapy is used incorrectly.


  1. Schwabe U. Paffrath D. (1998) (eds). Arzneiverordnungsreport 1998. Springer, Heidelberg.
  2. Gorter RW. Iscador. Townsend Letter for Doctors and Patients. October 2002.
  3. Schulz V. Hansel R. Tyler VE. Rational Phytotherapy: A Physician’s Guide to Herbal Medicine. Trans. Terry C. Telger. 3rd Berlin, Germany: Springer, 1998.
  4. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd New York, NY: John Wiley & Sons, 1996.
  5. Blumenthal M et al. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  6. Bussing A, Troger W, Stumpt C, Schietzel M. Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life. Anticancer Res. 2008 May-June, 28(3B), 1893-7.
  7. Boie, D.; Gutsch, J.:

[Mistletoe in colon and rectal cancer]. Krebsgeschehen 23, 1980, 65-76.

  • Boie D., Gutsch J., Burkhardt R. [Treatment of liver metastasis of various primary tumors with mistletoe]. Therapiewoche 31, 1981, 1855-1869.
  • C-Commission, Federal Health Administration Germany: Monography Viscum album.
  • Douwes FR, Kalden M, Frank G, Holzhauer P. [Treatment of advanced colorectal cancer]. Deutsche Zeitschrift fur Onkologie 20, 3, 1988, 63-67.
  • Douwes FR, Wolfrum DI, Migeod F. [Results of a prospective randomized study of chemotherapy versus chemotherapy plus biological response modifier in metastatic colorectal cancer]. Krebsgeschehen 18, 6, 1986, 155-164.
  • Gutsch J. [State of mistletoe treatment in adult chronic myeloid leukemia]. Arztezeitschrift fur Naturheilverfahren 23, 9, 1982, 523-544.
  • Gutsch J, Kuhne A. [Pharmacological and clinical effects of the mistletoe extract]. Heilkunst 99(4), 1986, 156-172.
  • Paio BK, Wang YX, Xie GR, Mansmann U, Matthes H. Beuth J. Lin HS. Impact of complementary mistletoe extract treatment of quality of life in breast, ovarian, non small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Research 24, 2004, 303-310.
  • Auerbach L, Dostal V, Vaclavik-Fleck I, Kubista E, Rosenberger A Rieger S. Troger W. Schierholz JM. [Significantly higher level of activated naturalkiller cells in patients with breast cancer receiving a Viscum album extract during chemotherapy]. In: [Advances in mistletoe therapy, State of the art in research and clinic]. KVC-Verlag Essen, 2005.
  • Gutsch J. Berrger H. Scholz g, Denck H. [Prospective study in a radically operated breast cancer with polychemotherapy, mistletoe and untreated controls]. Deutsche Zeitschrift fur Onkologie 20, 4, 1988, 94-101.
  • Hellan J, Salzer G, Wutzlhofer F. [The operated breast cancer – a retrospective evaluation]. Springer Berlin Heidelberg 1990, 63-69.
  • Hollinsky C, Danmayr E. [Prognosis of small breast cancer (T1N0). Retrospective analysis of 516 cases]. Deutsche Zeitschrift fur Onkologie 19, 3, 1987, 77-83.
  • Salzer G, Frey S, Danmayr E. [Treatment of operated stomach cancer at the Ludwig-Boltzmann-Institute for Clinical Oncology]. Deutsche Zeitschrift fur Onkologie 22, 1, 1990, 21-25.
  • Salzer G. Hellan J, Danmayr E, Wutzlhofer F, Arbeiter K. [The operated colorectal cancer – a retrospective analysis]. Deutsche Zeitschrift fur Onkologie 24, 4, 1992, 103-107.
  • Hellan J. Danmayr E. Hellan M. [Status of complementary medicine in the treatment of cancer patients – illustrated on the basis of colorectal cancer]. Deutsche Zeitschrift fur Onkologie 27, 4, 1995, 85-94.
  • Beuth J, Schneider B, Schierholz JM. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res. 2008 Jan-Feb, 28(1B), 523-527.
  • Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer – a systematic review on controlled clinical trials. Eur J Med Res. 2003 Mar 27, 8(3), 109-119.
  • Horneber MA, Buesschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database System Review. 2008 Apr 16, (2):CD003297.